SCHEMBL31023643

SCHEMBL31023643

OC(c1ccc2ncccc2c1)c1ccc2ncccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.57
POLB P06746 2/20 0.57
RAB9A P51151 1/20 0.57
ALDH1A1 P00352 5/20 0.53
MAPT P10636 3/20 0.53
HTT P42858 2/20 0.53
KDM4E B2RXH2 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
CASP1 P29466 2/20 0.53
TP53 P04637 1/20 0.53
HSP90AA1 P07900 1/20 0.53
HSP90AB1 P08238 1/20 0.53
TSHR P16473 1/20 0.53
ATM Q13315 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MET P08581 3/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
MCL1 Q07820 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8917474 0.93 MET (0.54) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL21709860 0.89 NPC1 (0.57) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL4065050 0.85 NPC1 (0.53) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL188108 0.85 UGT2B7 (0.56) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL30745165 0.85 UGT2B7 (0.56) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL6791174 0.84 KDM4A (0.48) NPC1POLBRAB9AALDH1A1HTT
SCHEMBL13363674 0.84 ALDH1A1 (0.53) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL8918290 0.83 TSHR (0.52) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL9999689 0.82 MAPT (0.51) NPC1POLBRAB9AALDH1A1MAPT
SCHEMBL6852153 0.81 ALDH1A1 (0.52) NPC1POLBRAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL NPC1 602/4885POLB 760/4885RAB9A 665/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL NPC1 602/4885POLB 760/4885RAB9A 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.